Swiss Med Wkly 2007; 137:621-622.
About QuantiFERON(R)-TB Gold (QFT(TM)):
QFT(TM)- - a simple blood test -- is the first major advancement in TB diagnosis since the introduction of the tuberculin skin test (TST) over 100 years ago. The QFT(TM) test is based on measurement of a cell mediated immune response in TB-infected individuals. The T cells of these individuals are sensitized to TB, and respond to stimulation with peptides simulating those expressed by the TB causing bacteria, secreting a cytokine called interferon- a. QFT(TM) accurately measures the interferon-a response in a sensitive enzyme assay. QFT(TM) is unaffected by previous BCG vaccination and most other mycobacteria.
Unlike the TST, it requires only one patient visit, is a controlled laboratory test, and provides an objective, reproducible result that is not subject to interpretation based on a patient's relative risk factors for TB exposure.
Cellestis is a listed Australian biotechnology company commercializing QuantiFERON(R) technology for diagnosing TB and other diseases worldwide. The Company operates through subsidiaries in the USA, Europe and Australia.
For more information, visit http://www.cellestis.com or please contact one of our local spokespersons at:
Tel: +61 3 9571 3500 (tel)
(Contact Mr. George Dragovic)
Tel: +49 6151 428 590
|SOURCE Cellestis International|
Copyright©2007 PR Newswire.
All rights reserved